Skip to main content
Article image
tech4 min read

LSU receives USDA grant to develop a bird flu vaccine

Louisiana State University (LSU) received $2 million from the USDA to develop a vaccine against H5N1 bird flu in poultry. Since 2022, the outbreak has caused the loss of more than 168 million birds in the United States.

How does the veterinary team plan to administer the vaccine to poultry on a large scale?

Louisiana State University (LSU) received a $2 million grant from the U.S. Department of Agriculture (USDA) to develop a vaccine against bird flu in poultry, a disease that has decimated flocks and contributed to rising prices for products such as chicken and eggs in recent years.

The team at the LSU School of Veterinary Medicine obtained the grant to develop a vaccine that protects birds against the highly contagious H5N1 strain of avian influenza, commonly known as bird flu. The funds will support research into a vaccine capable of offering earlier and stronger protection against the virus in birds such as chickens, ducks and turkeys.

“Highly pathogenic avian influenza continues to pose a serious threat to animal health, the poultry industry and our nation's food supply,” said Mariano Carossino, associate professor at the LSU School of Veterinary Medicine and lead researcher on the project, in a statement.

The threat of the outbreak in the United States

Since the current outbreak began in 2022, bird flu has caused the loss of more than 168 million commercial and backyard birds nationwide. There is no treatment or cure for the disease, so poultry producers cull birds exposed to the virus.

Infected birds shed the virus in their saliva, mucus and droppings, and the disease spreads through direct contact or via contaminated water, feed and habitat. The highly contagious version of the virus is often fatal for poultry and can be transmitted to other animals, including farm herds and pets.

Human cases and transmission

Bird flu can also be transmitted to people who have contact with infected birds, although the risk is considered very low. The Centers for Disease Control and Prevention (CDC) lists 74 cases of the current strain of bird flu in people and three deaths since February 2024.

The first human case of bird flu in Louisiana was reported in December 2024, in the southwestern part of the state. The person died within a month, although state health authorities noted that they were over 65 years old and had underlying health problems. That same month the disease was detected in a backyard poultry flock in Bossier Parish, and a domestic cat in New Orleans tested positive for the virus in January 2025.

Symptoms of bird flu in humans are comparable to those of the more common seasonal flu strains — cough, sore throat, headache and mild fever — although eye infections have been frequent in the current outbreak. No cases of person-to-person transmission have been documented, and the virus cannot be transmitted by eating birds that are properly handled and cooked.

A different vaccine approach

The vaccine LSU plans to develop will be different from more traditional approaches. The research team expects to use nanobodies, small molecules derived from disease antibodies, to target the vaccine toward specialized immune cells that exist in the intestinal tract of birds.

The approach is designed to strengthen the body's defenses at the sites where bird flu infection usually begins, according to the research team. It is expected to prevent infection and amplify the bird's overall immune response to ward off the virus.

LSU intends to develop a vaccine that can be administered through drinking water and to chicks before they hatch, which would make it more practical for poultry producers to administer doses to a large number of birds, Carossino said.

“Our goal is to develop a vaccine that provides effective protection against the virus while also being practical for poultry producers to administer on a large scale,” he said.